Trinity Biotech (TRIB)
0.66
-0.05 (-6.75%)
At close: Mar 24, 2025, 3:47 PM
0.68
2.66%
After-hours: Mar 24, 2025, 07:33 PM EDT
-6.75% (1D)
| Bid | 0.66 |
| Market Cap | 377.73K |
| Revenue (ttm) | 161.81K |
| Net Income (ttm) | -55.65K |
| EPS (ttm) | -2.25 |
| PE Ratio (ttm) | -0.3 |
| Forward PE | -1.37 |
| Analyst | n/a |
| Ask | 0.69 |
| Volume | 39,253 |
| Avg. Volume (20D) | 2,279,755 |
| Open | 0.71 |
| Previous Close | 0.71 |
| Day's Range | 0.66 - 0.71 |
| 52-Week Range | 0.63 - 3.55 |
| Beta | 1.21 |
About TRIB
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; ...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Oct 21, 1992
Employees 380
Stock Exchange NASDAQ
Ticker Symbol TRIB
Website https://www.trinitybiotech.com
Next Earnings Release
Trinity Biotech is scheduled to release its earnings on Apr 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+78.95%
Trinity Biotech shares are trading higher after th...
Unlock content with
Pro Subscription
5 months ago
+5.46%
Trinity Biotech shares are trading higher after the company announced the acquisition of EpiCapture. Also, the company announced a strategic investment in Novus Diagnostics to advance development and commercialization of Novus' point-of-care diagnostic solutions.
